Results 91 to 100 of about 1,923,383 (256)

T cell receptor-engineered T cells for leukemia immunotherapy

Cancer Cell International, 2019
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy
Yikai Zhang, Yangqiu Li
doaj   +1 more source

Additional file 2: of Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

, 2016
Preparation of chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19).
Chengfei Pu (3443966), He Huang (50693), Aiyun Jin (3443960), Yongxian Hu (327027), Lei Xiao (166081), Bin Liang (228729), Yi Luo (143206), Jian Yu (141239), Qu Cui (198237), Jie Sun (74648), Jimin Shi (576453), Zhao Wu (3443963)   +11 more
core   +1 more source

Loss of E3 Ubiquitin Ligase RINES via CpG Methylation Relieves Suppression of STAT3 and MYC, Facilitating Multiple Tumorigeneses

Advanced Science, EarlyView.
Dysregulated protein modifications drive tumorigenesis. RINES, an E3 ubiquitin ligase, represses tumor cell proliferation and metastasis by facilitating RING domain‐dependent, ubiquitin–proteasome‐mediated degradation of STAT3 and MYC, which consequently restrains cancer stemness and oncogenic progression.
Lili Li, Ka Man Ng, Xingsheng Shu, Xiaoxue Chai, Kai Yau Wong, Gopesh Srivastava, Anthony T.C. Chan, Wai Yee Chan, Qian Tao   +8 more
wiley   +1 more source

Chimeric antigen receptor-natural killer

Journal of Bone Marrow Transplantation and Cellular Therapy
Chimeric antigen receptor (CAR) technology has transformed adoptive cell therapy, particularly through the success of CAR-T cells in hematologic malignancies.
Larissa Cardoso Zanetti, Raquel de Melo Alves Paiva, Lucila Nassif Kerbauy   +2 more
doaj   +1 more source

Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis

Advanced Science, EarlyView.
Engineered macrophages programmed in situ by LNP‐delivered IL‐6/4 fusion and LL37 mRNAs simultaneously dampen cytokine storm, promote M2‐like repair, and enhance direct bacterial killing in sepsis. This combinatorial strategy restores T cell and macrophage function, lowers organ bacterial burden, and improves survival, highlighting a precision, host ...
Tianyang Jie, Zheyu Zhang, Hao Zhang, Linke Bian, Penglong Zheng, Sijia Zhou, Minqi Wang, Mingyu Qu, Yufei Wang, Xinhua Qu, Bing Yue   +10 more
wiley   +1 more source

Supplementary Figure from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors

, 2022
Supplementary Figure from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid ...
Jessica Hong (15090075), Markku Miettinen (15049911), Mitchell Ho (15090090), Jingli Zhang (15090069), Sakshi Tomar (15090066), Manakamana Khanal (15090072), Ira Pastan (15085516), Qun Jiang (15090081), Manjistha Sengupta (15090084), Raffit Hassan (15090093), Abhilash Venugopalan (15090078), Nan Li (15090087)   +11 more
core   +2 more sources

Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead

Frontiers in Bioscience-Elite
Chimeric antigen receptor–engineered macrophages (CAR-Ms) are emerging as a transformative frontier in immunotherapy and represent a promising strategy for pancreatic cancer.
Palloma Porto Almeida, Leandro Martins de Freitas   +1 more
doaj   +1 more source

Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj   +1 more source

Repurposing a Small Molecule Plant Hormone as a Tunable ON‐Switch for CAR‐T Cell Immunotherapy

Advanced Science, EarlyView.
By engineering a receptor system integrating the plant auxin receptor AFB1 with its co‐receptor IAA7, we enable ligand‐dependent interactions triggered by the plant hormone auxins. This design allows rapid, reversible, and dose‐dependent T cell activation, resulting in potent cytotoxicity against B‐cell lymphoma in vitro and in vivo.
Hongxiang Zeng, Lei Zheng, Rongkun Tao, Sirui Zheng, Yanke Zhong, Yongxia Niu, Peng Zhang, Xiang Ma, Chen Yang, Min Zhang, Fuyu Duan, Jing Yang, Xuan Wei, Xiang Zhou, Zhenbiao Yang, Zhaoxi Sun, Qizhou Lian   +16 more
wiley   +1 more source

Chimeric antigen receptor T-cells in multiple myeloma: Present and future [PDF]

This is a brief summary of various general contemporary topics regarding chimeric antigen receptor (CAR) T-cells in multiple myeloma (MM)
Plata, Carlos
core   +2 more sources